重新评估替代终点在心力衰竭药物开发中的作用
Stephen J Greene1,2, Robert J Mentz1,2, Mona Fiuzat1
1Duke Clinical Research Institute, Durham, NC (S.J.G., R.J.M., M.F., C.M.O.).
Circulation
|October 26, 2018
概括
对心力衰竭 (HF) 的药物开发面临挑战,第二阶段试验往往有希望,但在第三阶段失败. 重新评估II期试验设计和替代终点对于有效的HF疗法至关重要.
科学领域:
- 心脏病学
- 临床试验
- 药物开发
背景情况:
- 心力衰竭 (HF) 药物开发越来越具有挑战性,缺乏急性HF和具有保留射出分量的HF的经过验证治疗方法.
- 在HF中,早期 (II期) 和晚期 (III期) 临床试验结果之间存在越来越大的分歧.
- 第二阶段的初步结果往往无法转化为成功的第三阶段试验.
相关概念视频
Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure Drugs: Inotropic Agents
1.5K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.5K
Heart Failure Drugs: β-Blockers
920
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
920
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K
Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K


